Immunovant, Inc.
IMVT NASDAQHealthcare ★★★★★Latest Earnings Below forecast↓
Date
Aug 6, 2026
ET
EPS Est.
-0.63
EPS Actual
-0.75
Revenue Est.
$7.1M
Revenue Actual
$7.1M
Next Earnings Report
Date
Nov 9, 2026 · Mon
Time
Pre-market
Fiscal Period
FY2027 Q2
EPS Est.
-0.73
Revenue Est.
$7.1M
Company Overview
Immunovant, Inc. (ticker IMVT) is listed on NASDAQ with a market cap of about $9.16B. Its next earnings report (FY2027 Q2) is expected on Nov 9, 2026 (ET), Pre-market, with consensus EPS of -0.73. In the last 15 reported quarters, EPS beat consensus estimates 5 times.
Actual EPS TrendRecently15Term · Feb 3, 2023 → Aug 6, 2026
Feb 3, 2023Range: -0.76 ~ -0.36Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | -0.63 | Below forecast↓-0.75 | $7.1M | $7.1M |
| May 20, 2026 | -- | -0.59 | Below forecast↓-0.73 | -- | -- |
| Feb 6, 2026 | -- | -0.72 | Above forecast↑-0.61 | $6M | -- |
| Nov 10, 2025 | -- | -0.72 | -0.73 | -- | -- |
| Aug 11, 2025 | -- | -0.69 | -0.60 | -- | -- |
| May 29, 2025 | -- | -0.71 | -0.64 | -- | -- |
| Feb 6, 2025 | -- | -0.73 | -0.76 | -- | -- |
| Nov 7, 2024 | -- | -0.61 | Below forecast↓-0.74 | -- | -- |
| Aug 6, 2024 | -- | -0.53 | -0.60 | -- | -- |
| May 29, 2024 | -- | -0.43 | Below forecast↓-0.52 | -- | -- |
| Feb 12, 2024 | -- | -0.43 | Above forecast↑-0.36 | -- | -- |
| Nov 9, 2023 | -- | -0.47 | -0.45 | -- | -- |
| Aug 10, 2023 | -- | -0.45 | Below forecast↓-0.57 | -- | -- |
| May 22, 2023 | -- | -0.43 | -0.46 | -- | -- |
| Feb 3, 2023 | -- | -0.39 | Below forecast↓-0.49 | -- | -- |
Original Filings (SEC)
10-Q2026-08-06 ↗
8-K2026-08-06 ↗
10-K2026-05-20 ↗
8-K2026-05-20 ↗
10-Q2026-02-06 ↗
8-K2026-02-06 ↗
8-K2025-12-12 ↗
8-K2025-12-11 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
